Implications of pharmacogenetics for oral anticoagulants metabolism

Current Drug Metabolism

Volumn 10, Issue 6, 2009, Pages 632-642

  Pérez Andreu, Virginia ^a,b   Roldán, Vanessa ^a,b   González Conejero, Rocío ^a,b   Hernández Romero, Diana ^c   Vicente, Vicente ^a,b   Marín, Francisco ^c  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Metabolism; Oral anticoagulants; Polymorphisms

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 CYP4F2; FISH OIL; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; IMMUNOLOGIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXIDOREDUCTASE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARBOXYLATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENANTIOMER; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HAPLOTYPE; HUMAN; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE;

ANTICOAGULANTS; HUMANS; PHARMACOGENETICS; THROMBOEMBOLISM;

EID: 70450133979     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789375432     Document Type: Review

References (92)

1. James, A.H.; Britt, R.P.; Raskino, C.L.; Thompson, S.G. Factors affecting the maintenance dose of warfarin. J. Clin. Pathol., 1992, 45(8), 704-706.
2. Cooper, G.M.; Johnson, J.A.; Langaee, T.Y.; Hua, Feng.; Stanaway, Ian.B.; Schwarz, Ute.I.; Ritchie, M.D.; Stein, C.M.; Roden, D.M.; Smith, J.D.; Veenstra, D.L.; Rettie, A.E.; Rieder, M.J. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood, 2008, 112(4), 1022-1027.
3. King, C.R.; Porche-Sorbet, R.M.; Gage, B.F.; Ridker, P.M.; Renaud, Y.; Phillips, M.S.; Eby, C. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am. J. Clin. Pathol., 2008,129(6), 876-883.
4. Schwarz, U.I.; Ritchie, M.D.; Bradford, Y.; Li, C.; Dudek, S.M.; Frye-Anderson, A.; Kim, R.B.; Roden, D.M.; Stein, C.M. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med., 2008, 358(10), 999-1008.
5. Gage, B.F.; Lesko, L.J. Pharmacogenetics of warfarin: regulatory, scientific and clinical issues. J. Thromb. Thrombol., 2008, 25(1), 45-51.
6. Furie, B.; Furie, B.C. The molecular basis of blood coagulation. Cell, 1988, 53(4), 505-518.
7. Buitenhuis, H.C.; Soute, B.A.; Vermeer, C. Comparison of the vitamins K1, K2 and K3 as cofactors for the hepatic vitamin K-dependent carboxylase. Biochim. Biophys. Acta, 1990, 1034(2), 170-175.
8. Hirsch, J.; Fuster, V.; Ansell, J.; Halperin, J.L. American Heart Association, American College of Cardiology Foundation. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. Circulation, 2003, 107(12), 1692-1711.
9. Cranenburg, E.C.; Schurgers, L.J.; Vermeer, C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb. Haemost., 2007, 98(1), 120-125.
10. Wallin, R.; Hutson, S.M. Warfarin and the vitamin K-dependent gamma-carboxylation system. Trends Mol. Med., 2004, 10(7), 299-302.
11. Murshed, M,; Schinke, T.; McKee, M.D.; Karsenty, G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J. Cell Biol., 2004, 165(5), 625-630 (Pubitemid 38765764)
12. Rost, S.; Fregin, A.; Ivaskevicius, V.; Conzelmann, E.; Hörtnagel, K.; Pelz, H.J.; Lappegard, K.; Seifried, E.; Scharrer, I.; Tuddenham, E.G.; Müller, C.R.; Strom, T.M.; Oldenburg, J. Mutations in VKORC cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004, 427(6974), 537-541. (Pubitemid 38209110)
13. Li, T.; Chang, C.Y; Jin, D.Y.; Lin, P.J.; Khvorova, A.; Stafford, D.W. Identification of the gene for vitamin K epoxide reductase. Nature, 2004, 427(6974), 541-544.
14. Oldenburg, J.; Marinova, M,; Müller-Reible, C.; Watzka, M. The vitamin K cycle. Vitam. Horm., 2008, 78, 35-62.
15. Palareti, G.; Legnani, C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Pharmacokinetics, 1996, 30(4), 300-313.
16. Brekenridge, A.M. Oral anticoagulant drugs: pharmacokinetic aspects. Semin. Hematol., 1978, 15(1), 19-26. (Pubitemid 8262977)
17. Kelly, J.G.; O'Malley, K. Clinical pharmacokinetics of oral anticoagulants. Clin. Pharmacokinet., 1979, 4(1), 1-15.
18. Rettie, A.E.; Korzekwa, K.R.; Kunze, K.L.; Lawrence, R.F.; Eddy, A.C.; Aoyama, T.; Gelboin, H.V.; Gonzalez, F.J.; Trager, W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin -drug interactions. Chem. Res. Toxicol., 1992, 5(1), 54-59.
19. Kaminsky, L.S.; Zhang, Z. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
20. Wang, P.P.; Beaune, P.; Kaminsky, L.S.; Dannan, G.A.; Kadlubar, F.F.; Larrey, D.; Guengerich, F.P. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry, 1983, 22(23), 5375-5383.
21. Brian, W.R.; Sari, M.A.; Iwasaki, M.; Shimada, T.; Kaminsky, L.S.; Guengerich, F.P. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 1990, 29(51), 11280-11292.
22. Kaminsky, L.S.; Dunbar, D.A.; Wang, P.P.; Beaune, P.; Lorrey, D.; Guengerich, F.P.; Schnellmann, R.G.; Sipes, I.G. Human hepatic cytochrome P-450 compositions as probed by in vitro microsomal metabolism of warfarin. Drug Metab. Dispos., 1984, 12(4), 470-477. (Pubitemid 14091824)
23. Hermans, J.J.; Thijssen, H.H. The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences. Biochem. Pharmacol., 1989, 38(19), 3365-3370.
24. Yasar, U.; Eliasson, E.; Dahl, M.L.; Johansson, I.; Ingelman- Sundberg, M.; Sjöqvist, F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun., 1999, 254(3), 628-631. (Pubitemid 29290517)
25. Takahashi, H.; Kashima, T.; Nomizo, I.; Muramoto, N.; Shimizu, T.; Nasu, K.; Kubota, T.; Kimura, S.; Echizen, H. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C919 genotypes. Clin. Pharmacol. Ther., 1998, 63(5), 519-528. (Pubitemid 28277273)
26. Lee, C.R.; Goldstein, J.A.; Pieper, J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 2002, 12(3), 251-263.
27. Kuehl, P.; Zhang, J.;Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J. et al. Sequence diversity in CYP3A5 expression. Nat. Genet., 2001, 27(4), 383-391.
28. Gulseth, M.P.; Grice, G.R.; Dager, W.E. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am. J. Health Syst. Pharm., 2009, 15(2), 123-133.
29. Klotz, U. Interactions of analgesics with other drugs. Am. J. Med., 1983, 75(5), 133-138
30. Mahe, I.; Bertrand, N. ; Drouet, L. ; Bal Dit Sollier, C. ; Simoneau, G. ; Mazoyer, E. ; Caulin, C. ; Bergmann, J.F. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica, 2006, 91(12), 797-802.
31. Thijssen, H.H.; Soute, B.A.; Verboot, L.M.; Claessens, J.G. Paracetamol (acetaminophen warfarin interaction: nAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb. Haemost., 2004, 92(4), 797-802.
32. Dale, J.; Myhre, E.; Loew, D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am. Heart J., 1980, 99(6), 46-49.
33. Schulman, S.; Henrinksson, K. Interaction of ibuprofen and warfarin on primary haemostasis. Br. J. Rheumatol., 1989, 38(1), 46-49. (Pubitemid 19107401)
34. O'Reilly, R.A. The stereoselective interaction of warfarin and metronidazole in man. N. Engl. J. Med., 1976, 295(7), 354-357.
35. Betchtold, H.; Andrassay, K.; Jahnchen, E.; Koderisch, J.; Koderisch, H.; Weilemann, L.S.; Sonntag, H.G.; Ritz, E. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb. Haemost., 1984, 51(3), 358-361.
36. O'Reilly, R.A.; Trager, W.F.; Rettie, A.E.; Goulart, D.A. Interaction of amiodarone with racemic warfarin and its separated enantimorphs in humans. Clin. Pharmacol. Ther., 1987, 42(3), 290-294.
37. Toon, S.; Low, L.K.; Gibaldi, M.; Trager, W.F.; O'Reilly, R.A.; Motley, C.H.; Goulart, D.A. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther., 1986, 39(1), 15-24.
38. Yin,T.; Miyata, T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC - rationale and perspectives. Thromb. Res., 2007, 120(1), 1-10. (Pubitemid 46601582)
39. Xie, H.G.; Prasad, H.C.; Kim, R.B.; Stein, C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev., 2002, 54(10), 1257-1270.
40. Crespi, C.L.; Miller, V.P. The R144C change in the CYP2C9*2 allele alters interaction in the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics, 1997, 7(3), 203-210. (Pubitemid 27290634)
41. Both, S.L.; Charnley, J.M.; Sadowski, J.A. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with a constant vitamin K1 content. Thromb. Haemost., 1997, 77(3), 504-509.
42. Takanashi, K.; Tainaka, H.; Kobayashi, K.; Yasumori, T.; Hosakawa, M.; Chiba, K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics, 2000, 10(2), 95-104.
43. Rettie, A.E.; Wienkers, L.C.; Gonzales, F.J.; Trager, W.F.; Korzekwa, K.R. Impaired (S)-warfarin metabolism catalised by the R144C allelic variant of CYP2C9. Pharmacogenetics, 1994, 4(1), 39-42.
44. Haining, R.L.; Hunter, A.P.; Veronese, M.E.; Trager, W.F.; Rettie, A.E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 135L mutant forms. Arch. Biochem. Biophys., 1996, 333(2), 447-458.
45. Sullivan-Klose, T.H.; Ghanayem, B.L.; Bell, D.A.; Zhang, Z.Y.; Kaminsky, L.S.; Shenfield, G.M.; Miners, J.O.; Birkett, D.J.; Goldstein, J.A. The role of the CYP2C-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6(4), 341-349.
46. Ansell, J.; Hirsch, J.; Hylek, E.; Jacobson, A.; Crowther M.; Palareti, G.P. Pharmacologic and management of the Vitamin K Antagonist. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2008, 13(6), 160S-198S.
47. rd; Johnson, N.; Antonino- Green, D.; Lacefield, N.; Bukaveckas, B.L.; Valdes, R. Jr. Warfarin dose ajustements based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis, 2002, 14(3), 227-232.
48. Higashi, M.K.; Veenstra, D.L.; Kondo, L.M.; Wittkowsky, A.K.; Srinouanprachanh, S.L.; Farin, F.M.; Rettie, A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes Turing warfarin therapy. JAMA, 2002, 287(13), 1690-1698.
49. Carlsquist, J.F.; Horne, B.D.; Muhlestein, J.B.; Lappé, D.L.; Whiting, B.M.; Kolek, M.J.; Clarke, J.L.; James, B.C.; Anderson, J.L. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis., 2006, 22(3), 191-197. (Pubitemid 44857780)
50. Schwarz, U.I.; Ritchie, M.; Bradford, Y.; Li, C.; Dudek, S.M.; Frye-Anderson, A.; Kim, R.B.; Roden, D.M.; Stein, C.M. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med., 2008, 358(10), 999-1008.
51. Taube, J.; Halsall, D.; Baglin, T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96(5), 1816-1819. (Pubitemid 30661066)
52. Margaglione, M.; Colaizzo, D.; D'Andrea, G.; Brancaccio, V.; Ciampa, A.; Grandone, E.; Di Minno, G. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost., 2000, 84(5), 775-778. (Pubitemid 30946935)
53. Khon, M.H.; Pelz, H.J. A gene-anchored map position of the rat warfarin resistence locus, Rw, and its orthologs in mice and humans. Blood, 2000, 96(5), 1996-1998.
54. Rieder, M.J.; Reiner, A.P.; Gage, B.F.; Nickerson, D.A.; Eby, C.S.; McLeod, H.L.; Blough, D.K.; Thummel, K.E.; Veenstra, D.L.; Rettie, A.E. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med., 2005, 352(22), 2285-2293.
55. Wang, D.; Chen, H.; Momary, K.M.; Cavallari, L.H.; Johnson, J.A.; Sadée, W. Regulatory polymorphism in Vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood, 2009, 113(6), 1393-1394.
56. D'Andrea, G.; D'Ambrosio, R.L.; Di Perna, P.; Chetta, M.; Santacroce, R.; Brancaccio, V.; Grandone, E.; Margaglione, M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 2005, 105(2), 645-649. (Pubitemid 40070748)
57. Lee, S.C.; Ng, S.S.; Oldenburg, J.; Chong, P.Y.; Rost, S.; Guo, J.Y.; Yap, H.L.; Rankin, S.C.; Khor, H.B.; Yeo, T.C.; Ng, K.S.; Soong, R.; Goh, B.C. Interethnic variability of warfarin maintenance requirement in explained by VKORC genotype in an Asian population. Clin. Pharmacol. Ther., 2006, 79(3), 197-205.
58. Takahashi, H.; Wilkinson, G.R.; Nutescu, E.A.; Morita, T.; Ritchie, M.D.; Scordo, M.G.; Pengo, V.; Barban, M.; Padrini, R.; Ieiri, I.; Otsubo, K.; Kashima, T.; Kimura, S.; Kijima, S.; Echizen, H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics, 2006, 16(2), 101-110. (Pubitemid 43145678)
59. Sconce, E.; Khan, T.I.; Wynne, H.A.; Avery, P.; Monkhouse, L.; King, B.P.; Wood, P.; Kesteven, P.; Daly, A.K.; Kamali, F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characterisitcs upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106(7), 2329-2333. (Pubitemid 41510803)
60. Harrington, D.J.; Gorska, R.; Wheeler, R.; Davidson, S.; Murden, S.; Morse, C.; Shearer, M.J.; Mumford, A.D. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J. Thromb. Haemost., 2008, 6(10), 1663-1670.
61. D'Ambrosio, R.L.; D'Andrea, G.; Cafolla, A.; Faillace, F.; Margaglione, M. A new variant vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. J. Thromb. Haemost., 2007, 5(1), 191-193. (Pubitemid 44921089)
62. Loebstein, R.; Dvoskin, I.; Halkin, H.; Vecsler, M.; Lubetsky, A.; Rechavi, G.; Amariglio, N.; Cohen, Y.; Ken-Dror, G.; Almog, S.; Gak, E. A coding VKORC Asp36Tyr polymorphism predispose to warfarin resistance. Blood, 2007, 109(6), 2477-2480. (Pubitemid 46425891)
63. Thacker, S.M.; Grice, G.E.; Milligan, P.E.; Gage, B.F. Dosing anticoagulant therapy with coumarins drugs: is genotyping useful? Yes. J. Thromb. Haemost., 2008, 6(9), 1445-1449.
64. The International Warfarin Pharmacogenetics Consortium. estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 2009, 360(8), 753-764
65. Iein, I.; Takane, H.; Hirota, T.; Otsubo, K.; Higuchi, S. Genetic polymorphisms in drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert. Opin. Drug Metab. Toxicol., 2006, 2(5), 651-674. (Pubitemid 46127066)
66. Zhou, S.F.; Di, Y.M.; Chan, E.; Du, Y.M. ;Chow, V.D.; Xue, C.C.; Lai, X.; Wang, J.C.; Li, C.G.; Tian, M.,; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab., 2008, 9(8), 738-784.
67. Wadelius, M.; Sörlin, K.; Wallerman, O.; Karlson, J.; Yue, Q.Y; Magnusson, P.K.E.; Wadelius, C.; Melhus, H. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenet. J., 2004, 4(1), 40-48. (Pubitemid 38256604)
68. McDonald, M.G.; Rieder, M.J.; Nakano, M.; Hsia, C.K.; Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 2009, 75(6), 1337-1346.
69. Caldwell, M.D.; Awad, T.; Johnson, J.A.; Gage, B.F.; Falkowski, M.; Gardina, P.; Hubbard, J.; Turpaz, Y.; Langaee, T.Y.; Eby, C.; King, C.R.; Brower, A.; Schmelzer, J.R.; Glurich, I.; Vidaillet, H.J.; Yale, S.H.; Qi Zhang, K.; Berg, R.L.; Burmester, J.K. CYP4F2 genetic variants alters required warfarin dose. Blood, 2008, 111(8), 4106-4112.
70. Wadelius, M.; Chen, L.Y.; Downes, K.; Ghori, J.; Hunt, S.; Eriksson, N.; Wallerman, O.; Melhus, H.; Wadelius, C.; Bentley, D.; Deloukas, P. Common VKORC1 and GGCX polymorphism associated with warfarin dose. Pharmacogenom. J., 2005, 5(4), 262-270.
71. Vecsler, M.; Loebstein, R.; Almog, S.; Kurnik, D.; Goldman, B.; Halkin, H.; Gak, E. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost., 2006, 95(2), 205-211.
72. Herman, D.; Peternel, P.; Stegnar, M.; Breskvar, K.; Dolzan, V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost., 2006, 95(5), 782-787.
73. Shikata, E.; Ieiri, I.; Ishiguro, S.; Aono, H.; Inoue, K.; Koide, T.; Ohgi, S.; Otsubo, K. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood, 2004, 103(7), 2630-2635. (Pubitemid 38393017)
74. Wajh, N.; Sane, D.C.; Hutson, S.M.; Wallin, R. The inhibitory effect of calumenin on the vitamin K-dependent gammacarboxylation system. Characterization of the system in normal and warfarin-resistant rats. J. Biol. Chem., 2004, 279(24), 25276-25283. (Pubitemid 38756780)
75. Vecsler, M.; Loebstein, R.; Almog, S.; Kurnik, D.; Goldman, B.; Halkin, H.; Gak, E. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost., 2006, 95(2), 205-211.
76. D'Ambrosio, R.L.; D'Andrea, G.; Capucci, F.; Chetta, M.; Di Perna, P.; Brancaccio, V.; Grandone, E.; Margaglione, M. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica, 2004, 89(12), 1510-1516. (Pubitemid 39643520)
77. Herman, D.; Peternel, P.; Stegnar, M.; Breskvar, K.; Dolzan, V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost., 2006, 95(5), 782-787.
78. Beinema, M.; Browers, J.R.; Schalekamp, T.; Wilffert, B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb. Haemost., 2008, 100(6), 1052-1057.
79. Caraco, Y.; Chajek-Shaul, T. The incidence and clinical significance of amiodarone and acenocoumarol interaction. Thromb. Haemost., 1991, 65(3), 906-908. (Pubitemid 20005001)
80. Jose. L.; Binila, C.; Chandy, S.J.; Mathews, J.E.; Mathews, K.P. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. J. Assoc. Physicians India, 2008, 56, 250-252.
81. Schalekamp, T.; van Geest-Daalderop, J.H.; Kramer, M.H.; van Holten-Verzantvoort, A.T.; de Boer, A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur. J. Clin. Pharmacol., 2007, 63(4), 335-343.
82. Mondillo, S.; Ballo, P.; Galderisi, M. Rosuvastatin-acenocoumarol interaction. Clin. Ther., 2005, 27(6), 782-784.
83. Llibre, J.M.; Romeu, J.; Lopez, E.; Sirera, J. Severe interaction between ritonavir and acenocoumarol. Ann.Pharmacother., 2002, 36(4), 621-623.
84. Visser, L.E.; van Vliet, M.; van Schaik, R.H.; Kasbergen, A.A.; De Smet, P.A.; Vulto, A.G.; Hofman, A.; van Duijn, C.M.; Stricker, B.H. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 2004, 14(1), 27-33. (Pubitemid 38183959)
85. Bodin, L. ; Verstuyft, C.; Tregouet, D.A.; Robert, A.; Dubert, L.; Funck-Brentano, C.; Jaillon, P. ; Beaune, P. ; Laurent-Puig, P. ; Becquemont, L. ; Loriot, M.A. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106(1), 135-140.
86. Perez-Andreu, V.; Roldan, V.; Anton, A.I.; Garcia-Barbera, N.; Corral, J.; Vicente, V.; Gonzalez-Conejero, R. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 2009, 113(20), 4977-4979.
87. Gonzalez-Conejero, R.; Corral, J.; Roldan, V.; Vicente, V. Gamma-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. Thromb. Res., 2008, 122(3), 429-431.
88. Gonzalez- Conejero, R.; Corral, J.; Roldan, V.; Ferrer, F.; Sánchez-Serrano, I.; Sánchez-Blanco, J.J.; Marín, F.; Vicente, V. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. Thromb. Haemost., 2007, 5(8), 1701-1706. (Pubitemid 47091414)
89. Saraeva, R.B.; Paskaleva, D.; Doucheva, E.; Eap, C.B.; Ganev, V.S. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19 CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J. Clin. Pharmcol. Ther., 2007, 32(6), 641-649
90. Ufer, M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin. Pharmacokinet., 2005, 44(12), 1227-1246. (Pubitemid 41832565)
91. Werner, E.; Werner, U.; Wuerfel, A.; Grosch, A.; Lestin, H.G.; Eschenhagen, T.; Rau, T. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur. J. Clin. Pharmacol., 2009, 65(8), 783-788
92. Stehle, S.; Kirchheiner, J.; Lazar, A.M.; Fuhr, U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinetic, 2008, 47(9), 565-594